Remaking Chiron

Sellside wish list

Sean Lance, Chiron Corp.'s incoming CEO, inherits a situation that has led disappointed investors to shun the stock. Last week, BioCentury asked a sampling of sellside analysts what they believe Lance needs to do to revive interest on the Street. - Eric Pierce

Peter Ginsberg, Piper Jaffray

The drivers that will bring investors back to Chiron are a focus on higher growth markets and cost-cutting throughout the company. Sean Lance will drive that process. Lance was a focal point in the merger between Glaxo and Wellcome, and was very involved in the rationalization of both